Fig. 4
From: Intratumoral administration of mRNA COVID-19 vaccine delays melanoma growth in mice
Enhanced therapeutic effects of mRNA-1273 and immune checkpoint therapy (ICT). B16F10 (A) tumor growth curves and (B) survival curves following a single 20 µL IT injections of 3 µg mRNA-1273 or empty LNP combined with ICT 4 days later (n = 4 mice/group, n = 8 mice total); *p = 0.043, **p = 0.0016. PBS + ICT control group reached tumor endpoint before ICT treatments were completed. HR of mRNA-1273 + ICT/LNP + ICT is 0.050 with log-rank (Mantel-Cox) test, *p = 0.011. B16F10 (C) tumor growth curves (*** p < 0.001, ****p < 0.0001) and (D) survival curves following 3 doses of a 20 µL IT injections of 3 µg mRNA-1273 or empty LNP followed by ICT 1 day later (n = 5 mice/group, n = 10 mice total); HR of mRNA-1273 + ICT 3X/LNP + ICT 3X is 0.043 with log-rank (Mantel-Cox) test, *p = 0.0039. Tumor growth data shown as mean (SD), unpaired student t test comparing tumor volume post treatment.
